Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrea O. Rossetti is active.

Publication


Featured researches published by Andrea O. Rossetti.


Annals of Neurology | 2010

Prognostication after cardiac arrest and hypothermia: A prospective study

Andrea O. Rossetti; Mauro Oddo; Giancarlo Logroscino; Peter W. Kaplan

Current American Academy of Neurology (AAN) guidelines for outcome prediction in comatose survivors of cardiac arrest (CA) have been validated before the therapeutic hypothermia era (TH). We undertook this study to verify the prognostic value of clinical and electrophysiological variables in the TH setting.


Epilepsia | 2015

A definition and classification of status epilepticus--Report of the ILAE Task Force on Classification of Status Epilepticus.

Eugen Trinka; Hannah R. Cock; Dale C. Hesdorffer; Andrea O. Rossetti; Ingrid E. Scheffer; Shlomo Shinnar; Simon Shorvon; Daniel H. Lowenstein

The Commission on Classification and Terminology and the Commission on Epidemiology of the International League Against Epilepsy (ILAE) have charged a Task Force to revise concepts, definition, and classification of status epilepticus (SE). The proposed new definition of SE is as follows: Status epilepticus is a condition resulting either from the failure of the mechanisms responsible for seizure termination or from the initiation of mechanisms, which lead to abnormally, prolonged seizures (after time point t1). It is a condition, which can have long‐term consequences (after time point t2), including neuronal death, neuronal injury, and alteration of neuronal networks, depending on the type and duration of seizures. This definition is conceptual, with two operational dimensions: the first is the length of the seizure and the time point (t1) beyond which the seizure should be regarded as “continuous seizure activity.” The second time point (t2) is the time of ongoing seizure activity after which there is a risk of long‐term consequences. In the case of convulsive (tonic–clonic) SE, both time points (t1 at 5 min and t2 at 30 min) are based on animal experiments and clinical research. This evidence is incomplete, and there is furthermore considerable variation, so these time points should be considered as the best estimates currently available. Data are not yet available for other forms of SE, but as knowledge and understanding increase, time points can be defined for specific forms of SE based on scientific evidence and incorporated into the definition, without changing the underlying concepts. A new diagnostic classification system of SE is proposed, which will provide a framework for clinical diagnosis, investigation, and therapeutic approaches for each patient. There are four axes: (1) semiology; (2) etiology; (3) electroencephalography (EEG) correlates; and (4) age. Axis 1 (semiology) lists different forms of SE divided into those with prominent motor systems, those without prominent motor systems, and currently indeterminate conditions (such as acute confusional states with epileptiform EEG patterns). Axis 2 (etiology) is divided into subcategories of known and unknown causes. Axis 3 (EEG correlates) adopts the latest recommendations by consensus panels to use the following descriptors for the EEG: name of pattern, morphology, location, time‐related features, modulation, and effect of intervention. Finally, axis 4 divides age groups into neonatal, infancy, childhood, adolescent and adulthood, and elderly.


Resuscitation | 2014

Prognostication in comatose survivors of cardiac arrest: An advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine ☆

Claudio Sandroni; Alain Cariou; Fabio Cavallaro; Tobias Cronberg; Hans Friberg; C.W.E. Hoedemaekers; Janneke Horn; Jerry P. Nolan; Andrea O. Rossetti; Jasmeet Soar

OBJECTIVES To review and update the evidence on predictors of poor outcome (death, persistent vegetative state or severe neurological disability) in adult comatose survivors of cardiac arrest, either treated or not treated with controlled temperature, to identify knowledge gaps and to suggest a reliable prognostication strategy. METHODS GRADE-based systematic review followed by expert consensus achieved using Web-based Delphi methodology, conference calls and face-to-face meetings. Predictors based on clinical examination, electrophysiology, biomarkers and imaging were included. RESULTS AND CONCLUSIONS Evidence from a total of 73 studies was reviewed. The quality of evidence was low or very low for almost all studies. In patients who are comatose with absent or extensor motor response at ≥72 h from arrest, either treated or not treated with controlled temperature, bilateral absence of either pupillary and corneal reflexes or N20 wave of short-latency somatosensory evoked potentials were identified as the most robust predictors. Early status myoclonus, elevated values of neuron specific enolase at 48 72 h from arrest, unreactive malignant EEG patterns after rewarming, and presence of diffuse signs of postanoxic injury on either computed tomography or magnetic resonance imaging were identified as useful but less robust predictors. Prolonged observation and repeated assessments should be considered when results of initial assessment are inconclusive. Although no specific combination of predictors is sufficiently supported by available evidence, a multimodal prognostication approach is recommended in all patients.


Neurology | 2009

Predictors of awakening from postanoxic status epilepticus after therapeutic hypothermia

Andrea O. Rossetti; Mauro Oddo; Lucas Liaudet; Peter W. Kaplan

PREDICTORS OF AWAKENING FROM POSTANOXIC STATUS EPILEPTICUS AFTER THERAPEUTIC HYPOTHERMIA To the Editor: We read with interest the article by Rossetti et al.,1 who studied 6 cardiac arrest (CA) cases with postanoxic status epilepticus (PSE) treated with therapeutic hypothermia. The authors highlight important observations about EEG in the age of therapeutic hypothermia. The study raises the question: If specific EEG patterns emerge after CA, would these patterns now represent a treatable CA with potential for better outcomes? However, the authors apparently did not perform EEG during the hypothermic period in which vecuronium was used. Nonetheless, the authors’ data showed half of their cases with clinically evident seizures at the bedside confirmed by EEG while the other half had PSE detected only on EEG in coma. The authors’ observations demonstrate that not all clinically evident post CA myoclonic jerking represents myoclonus status epilepticus, which is a poor prognostic sign. Recently published American Academy of Neurology guidelines emphasized the utility of EEG after CA.2 It has been our observation in 2 years of using hypothermia after CA that myoclonic jerks after CA are an ominous sign especially in concert with absent or partially absent brainstem reflexes. We find the authors’ study important for clinicians, since all myoclonic jerking seen at the bedside after CA should not be interpreted as indicative of myoclonus status epilepticus without EEG confirmation. To do so could lead to a self-fulfilling prophecy of poor outcome and untreated status epilepticus. Additionally, the majority of the authors’ cases with PSE on EEG had background reactivity, intact brainstem reflex testing, and intact N20 responses on somatosensory evoked potential testing. This group of patients might be expected to do better than most. For example, we treated 26 patients with hypothermia after cardiac arrest over 2 years (mixed in and out of hospital arrest, ventricular fibrillation, pulseless electrical activity, and asystole) and observed 3 cases (11%) with severe myoclonic jerking after hypothermia, sedation, and muscle relaxation was lifted. In these patients, there was typically partial loss of brainstem reflexes prehypothermia and posthypothermia, and in 1 case absent N20 potentials. In 2 of our cases, the EEG indicated a myoclonus status epilepticus pattern, in which the background is typically suppressed, unreactive, and alternating bursts of activity correlated with myoclonic jerks.3 Whether the hypothermia improves the EEG patterns relative to clinical outcomes during the period of therapeutic hypothermia is still unclear.


Neurology | 2011

Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma

Michael Weller; Thierry Gorlia; J. G. Cairncross; M. J. van den Bent; Warren P. Mason; Karl Belanger; Alba A. Brandes; Ulrich Bogdahn; David R. Macdonald; Peter Forsyth; Andrea O. Rossetti; Denis Lacombe; René-Olivier Mirimanoff; C. J. Vecht; Roger Stupp

Objective: This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma. Methods: The European Organization for Research and Treatment of Cancer (EORTC) 26981–22981/National Cancer Institute of Canada (NCIC) CE.3 clinical trial database of radiotherapy (RT) with or without temozolomide (TMZ) for newly diagnosed glioblastoma was examined to assess the impact of the interaction between AED use and chemoradiotherapy on survival. Data were adjusted for known prognostic factors. Results: When treatment began, 175 patients (30.5%) were AED-free, 277 (48.3%) were taking any enzyme-inducing AED (EIAED) and 135 (23.4%) were taking any non-EIAED. Patients receiving valproic acid (VPA) only had more grade 3/4 thrombopenia and leukopenia than patients without an AED or patients taking an EIAED only. The overall survival (OS) of patients who were receiving an AED at baseline vs not receiving any AED was similar. Patients receiving VPA alone (97 [16.9%]) appeared to derive more survival benefit from TMZ/RT (hazard ratio [HR] 0.39, 95% confidence interval [CI] 0.24–0.63) than patients receiving an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53–0.90) or patients not receiving any AED (HR 0.67, 95% CI 0.49–0.93). Conclusions: VPA may be preferred over an EIAED in patients with glioblastoma who require an AED during TMZ-based chemoradiotherapy. Future studies are needed to determine whether VPA increases TMZ bioavailability or acts as an inhibitor of histone deacetylases and thereby sensitizes for radiochemotherapy in vivo.


Epilepsia | 2010

Refractory status epilepticus: A prospective observational study

Jan Novy; Giancarlo Logroscino; Andrea O. Rossetti

Purpose:  Status epilepticus (SE) that is resistant to two antiepileptic compounds is defined as refractory status epilepticus (RSE). In the few available retrospective studies, estimated RSE frequency is between 31% and 43% of patients presenting an SE episode; almost all seem to require a coma induction for treatment. We prospectively assessed RSE frequency, clinical predictors, and outcome in a tertiary clinical setting.


Critical Care Medicine | 2008

Early predictors of outcome in comatose survivors of ventricular fibrillation and non-ventricular fibrillation cardiac arrest treated with hypothermia: a prospective study.

Mauro Oddo; Vincent Ribordy; François Feihl; Andrea O. Rossetti; Marie-Denise Schaller; René Chioléro; Lucas Liaudet

Objectives:Current indications for therapeutic hypothermia (TH) are restricted to comatose patients with cardiac arrest (CA) due to ventricular fibrillation (VF) and without circulatory shock. Additional studies are needed to evaluate the benefit of this treatment in more heterogeneous groups of patients, including those with non-VF rhythms and/or shock and to identify early predictors of outcome in this setting. Design:Prospective study, from December 2004 to October 2006. Setting:32-bed medico-surgical intensive care unit, university hospital. Patients:Comatose patients with out-of-hospital CA. Interventions:TH to 33 ± 1°C (external cooling, 24 hrs) was administered to patients resuscitated from CA due to VF and non-VF (including asystole or pulseless electrical activity), independently from the presence of shock. Measurements and Main Results:We hypothesized that simple clinical criteria available on hospital admission (initial arrest rhythm, duration of CA, and presence of shock) might help to identify patients who eventually survive and might most benefit from TH. For this purpose, outcome was related to these predefined variables. Seventy-four patients (VF 38, non-VF 36) were included; 46% had circulatory shock. Median duration of CA (time from collapse to return of spontaneous circulation [ROSC]) was 25 mins. Overall survival was 39.2%. However, only 3.1% of patients with time to ROSC >25 mins survived, as compared to 65.7% with time to ROSC ≤25 mins. Using a logistic regression analysis, time from collapse to ROSC, but not initial arrest rhythm or presence of shock, independently predicted survival at hospital discharge. Conclusions:Time from collapse to ROSC is strongly associated with outcome following VF and non-VF cardiac arrest treated with therapeutic hypothermia and could therefore be helpful to identify patients who benefit most from active induced cooling.


Neurology | 2012

Early EEG correlates of neuronal injury after brain anoxia

Andrea O. Rossetti; Emmanuel Carrera; Mauro Oddo

Objectives: EEG and serum neuron-specific enolase (NSE) are used for outcome prognostication in patients with postanoxic coma; however, it is unclear if EEG abnormalities reflect transient neuronal dysfunction or neuronal death. To assess this question, EEG abnormalities were correlated with NSE. Moreover, NSE cutoff values and hypothermic EEG features related with poor outcome were explored. Methods: In a prospective cohort of 61 adults treated with therapeutic hypothermia (TH) after cardiac arrest (CA), multichannel EEG recorded during TH was assessed for background reactivity and continuity, presence of epileptiform transients, and correlated with serum NSE collected at 24–48 hours after CA. Demographic, clinical, and functional outcome data (at 3 months) were collected and integrated in the analyses. Results: In-hospital mortality was 41%, and 82% of survivors had good neurologic outcome at 3 months. Serum NSE and EEG findings were strongly correlated (Spearman rho = 0.45; p < 0.001). Median NSE peak values were higher in patients with unreactive EEG background (p < 0.001) and discontinuous patterns (p = 0.001). While all subjects with nonreactive EEG died, 5 survivors (3 with good outcome) had NSE levels >33 μg/L. Conclusion: The correlation between EEG during TH and serum NSE levels supports the hypothesis that early EEG alterations reflect permanent neuronal damage. Furthermore, this study confirms that absent EEG background reactivity and presence of epileptiform transients are robust predictors of poor outcome after CA, and that survival with good neurologic recovery is possible despite serum NSE levels> 33 μg/L. This underscores the importance of multimodal assessments in this setting.


Journal of Neurology | 2008

Status Epilepticus Severity Score (STESS)

Andrea O. Rossetti; Giancarlo Logroscino; Tracey A. Milligan; Costas Michaelides; Christiane Ruffieux; Edward B. Bromfield

BackgroundStatus epilepticus (SE) treatment ranges from small benzodiazepine doses to coma induction. For some SE subgroups, it is unclear how the risk of an aggressive therapeutic approach balances with outcome improvement. We recently developed a prognostic score (Status Epilepticus Severity Score, STESS), relying on four outcome predictors (age, history of seizures, seizure type and extent of consciousness impairment), determined before treatment institution. Our aim was to assess whether the score might have a role in the treatment strategy choice.MethodsThis cohort study involved adult patients in three centers. For each patient, the STESS was calculated before primary outcome assessment: survival vs. death at discharge. Its ability to predict survival was estimated through the negative predictive value for mortality (NPV). Stratified odds ratios (OR) for mortality were calculated considering coma induction as exposure; strata were defined by the STESS level.ResultsIn the observed 154 patients, the STESS had an excellent negative predictive value (0.97). A favorable STESS was highly related to survival (P < 0.001), and to return to baseline clinical condition in survivors (P < 0.001). The combined Mantel-Haenszel OR for mortality in patients stratified after coma induction and their STESS was 1.5 (95 % CI: 0.59–3.83).ConclusionThe STESS reliably identifies SE patients who will survive. Early aggressive treatment could not be routinely warranted in patients with a favorable STESS, who will almost certainly survive their SE episode. A randomized trial using this score would be needed to confirm this hypothesis.


Lancet Neurology | 2011

Management of refractory status epilepticus in adults: still more questions than answers

Andrea O. Rossetti; Daniel H. Lowenstein

Refractory status epilepticus (RSE) is defined as status epilepticus that continues despite treatment with benzodiazepines and one antiepileptic drug. RSE should be treated promptly to prevent morbidity and mortality; however, scarce evidence is available to support the choice of specific treatments. Major independent outcome predictors are age (not modifiable) and cause (which should be actively targeted). Recent recommendations for adults suggest that the aggressiveness of treatment for RSE should be tailored to the clinical situation. To minimise intensive care unit-related complications, focal RSE without impairment of consciousness might initially be approached conservatively; conversely, early induction of pharmacological coma is advisable in generalised convulsive forms of the disorder. At this stage, midazolam, propofol, or barbiturates are the most commonly used drugs. Several other treatments, such as additional anaesthetics, other antiepileptic or immunomodulatory compounds, or non-pharmacological approaches (eg, electroconvulsive treatment or hypothermia), have been used in protracted RSE. Treatment lasting weeks or months can sometimes result in a good outcome, as in selected patients after encephalitis or autoimmune disorders. Well designed prospective studies of RSE are urgently needed.

Collaboration


Dive into the Andrea O. Rossetti's collaboration.

Top Co-Authors

Avatar

Mauro Oddo

University of Lausanne

View shared research outputs
Top Co-Authors

Avatar

Jan Novy

University of Lausanne

View shared research outputs
Top Co-Authors

Avatar

Vincent Alvarez

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Vincent Alvarez

Brigham and Women's Hospital

View shared research outputs
Top Co-Authors

Avatar

Peter W. Kaplan

Johns Hopkins Bayview Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge